|
|
 |
|
Viewing report
|
|
|
|
Biogenerics 2005: A New Level Of Complexity
Datamonitor, Oct 2005, Pages: 286
Introduction
Biogenerics (or biosimilars, or follow-on proteins) could now enter the EU market in a matter of months, and the US by 2009. The prize awaiting biogeneric manufacturers such as Sandoz, Teva, and BioPartners is a global market worth $20 billion. Market fragmentation, product-specific constraints and new challenges in biotechnology, drug delivery and marketing will present major barriers to entry.
Scope
In-depth analysis of product types and brands under threat, their suitability for biogenerics, and the forecast impact of biogenerics
Coverage of 25 biogenerics companies, their portfolios, partnerships and strategy, and analysis of improved, proprietary superbiogenerics
Outline of regulatory progress, likely approval routes for biogenerics, and conflicting market pressures
Analysis of branded companies franchises under threat, their strategies to deal with biogenerics, and their likely success
Highlights
The EU regulatory pathway has progressed rapidly over the last two years, and we expect the first biogeneric to be approved by 2006. In the US immediate progress depends on the FDAs use of the controversial 505(b)(2) pathway for insulin and growth hormone. We nevertheless expects biogenerics to launch in the US by 2009.
Biogenerics will require an entirely new development and marketing strategy: marketing and patient support will be much more important, and this will favour companies with strong financial resources and commercial experience. Further in the future, the development of superbiogenerics (second-generation biogenerics), will be a vital opportunity.
Different product types will differ greatly in their suitability as targets for biogenerics. Market size and patent expiry are not the only two considerations, as proven by the minimal interest in insulin. Epoetin, CSFs and human growth hormone are expected to account for the majority of the $2.2 billion in forecast biogeneric sales by 2010.
Reasons to Purchase
Identify key potential partners and competitors in the emerging biogenerics industry and examine their products and strategies
Discover the advantages and drawbacks of key biogeneric product types, and learn the forecast levels of biogeneric competition within each class
Analyze and benchmark branded companies strategies to maintain market share and their likely success
Customers who bought this item also bought
A Guide to Biosimilars, Biogenerics and Follow-On Biologics
Competitor Analysis: Biogenerics & Therapeutic Proteins
Business Strategies for Different Types of Biogenerics
Toward a Biogenerics Market: The Regulatory Conundrum
Strategies for Biogeneric Success
Biogenerics: Drivers and Resistors of Market Development
Biogenerics: Challenges and Promise
Biosimilars, Biogenerics and Follow-On Biologics
Biogenerics - Global Strategic Business Report
The Biogenerics Market Outlook: An Analysis of Market Dynamics, Growth Drivers and Leading Players
The Anemia Market: Biogenerics and Second-Generation Products Drive Change
Strategic Analysis of the World Biogenerics Market
|
|
|
|
